Collegium Pharmaceutical (COLL) Competitors

Organon & Co. (NYSE:OGN) and Collegium Pharmaceutical (NASDAQ:COLL) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, community ranking, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Do analysts rate OGN or COLL?

Organon & Co. currently has a consensus price target of $21.33, indicating a potential upside of 44.44%. Collegium Pharmaceutical has a consensus price target of $42.60, indicating a potential upside of 37.86%. Given Organon & Co.'s higher probable upside, research analysts clearly believe Organon & Co. is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60

Do institutionals & insiders hold more shares of OGN or COLL?

77.4% of Organon & Co. shares are held by institutional investors. 1.4% of Organon & Co. shares are held by company insiders. Comparatively, 4.0% of Collegium Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Does the media refer more to OGN or COLL?

In the previous week, Organon & Co. had 2 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 6 mentions for Organon & Co. and 4 mentions for Collegium Pharmaceutical. Collegium Pharmaceutical's average media sentiment score of 1.63 beat Organon & Co.'s score of 0.78 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	2 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Collegium Pharmaceutical	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Does the MarketBeat Community believe in OGN or COLL?

Collegium Pharmaceutical received 368 more outperform votes than Organon & Co. when rated by MarketBeat users. Likewise, 65.25% of users gave Collegium Pharmaceutical an outperform vote while only 34.00% of users gave Organon & Co. an outperform vote.

Company	Underperform	Outperform
Organon & Co.	Outperform Votes 17 34.00%	Underperform Votes 33 66.00%
Collegium Pharmaceutical	Outperform Votes 385 65.25%	Underperform Votes 205 34.75%

Which has more volatility & risk, OGN or COLL?

Organon & Co. has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500.

Which has higher earnings & valuation, OGN or COLL?

Organon & Co. has higher revenue and earnings than Collegium Pharmaceutical. Organon & Co. is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.26B	0.61	$1.02B	$5.04	2.93
Collegium Pharmaceutical	$599.25M	1.66	$48.15M	$2.32	13.32

Is OGN or COLL more profitable?

Organon & Co. has a net margin of 20.30% compared to Collegium Pharmaceutical's net margin of 14.78%. Organon & Co.'s return on equity of 644.70% beat Collegium Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	20.30%	644.70%	8.12%
Collegium Pharmaceutical	14.78%	104.67%	18.38%

Summary

Collegium Pharmaceutical beats Organon & Co. on 10 of the 19 factors compared between the two stocks.